A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy

NCT02215330 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Central Serous Chorioretinopathy

Interventions

DRUG: Eplerenone
DRUG: Maltodextrin

Sponsor

Prim. Prof. Dr. Oliver Findl, MBA